Yıl: 2011 Cilt: 28 Sayı: 4 Sayfa Aralığı: 276 - 285 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile

Öz:
Amaç: Ankaferd BloodStopper® (ABS) bir bitkisel karışımıdır ve geleneksel Türk tıbbında uzun yıllardır kullanılmaktadır. ABS, T. vulgaris, G. glabra, V. vinifera, A. officinarum ve U. dioica bitkilerinin standartlaştırılmış en uygun karışımını ihtiva etmektedir. Temel etki mekanizması vital fizyolojik eritrosit birikimlerinin protein ağı yapısı oluşturmasıdır. Hemostatik etkileri in vivo ve in vitro çalışmalarda gösterilmiştir. ABS dış kanamalarda ve diş kanamalarında kontrollü klinik çalışmaları yapılmış güvenlik ve etkinlik raporları ile tescillenmiştir. Transkripsiyon faktörleri potansiyel olarak hemostatik ve diğer olası etkilerin merkezinde yer alabilir ve ABS uygulamalarından etkilenebilirler. Yöntem ve Gereçler: Bu çalışmada, ABS’nin endotelde ve olası transkripsiyon faktörleri değişimini HUVEC’lerde (insan umbilikal ven endotelyal hücreleri) ve eritrosit membran profilleri üzerindeki etkilerinin incelenmesi amaçlanmıştır. ABS, HUVE hücrelerine (75cm2 yüzeyde; ~%75 dolulukta), 5 μL ve 50 μL hacimlerde 5 ve 15 dakika uygulanmıştır. Bulgular: Transkripsiyon faktörlerinden AP2, AR, CRE/ATF1, CREB, E2F1-5, E2F6, EGR, GATA, HNF-1, ISRE, Myc-Max, NF-1, NFkB, p53, PPAR, SMAD 2/3, SP1, TRE/AP1, YY1’in aktivasyonların- da artış gözlenmiştir. Kandan eritrosit membranı izolasyonundan sonra, protein komplekslerinin denatürasyona rağmen çözünmemiş halde kalmaktadır ve bu kompleksler sıcaklığa ve deterjana dayanıklıdır. Sonikasyon ve tripsin muamelesinden sonra bu kompleksin ayrıştığı ve eritrosit membran proteinlerinin ortaya çıktığı SDS-PAGE’de gözlemlenmiştir. Sonuç: Sonuçlar gözönüne alındığında hemostatik ajan ankaferd’in kanamaları durdururken çok hızlı ve sağlam bir ağ oluşturmaktadır ve uygulandığı bölgedeki hücrelerin içinde de etkili olup transkripsiyon faktörleri seviyelerini de etkileyerek birçok biyolojik mekanizmalar üzerinde etkili olabilir.
Anahtar Kelime:

Konular: Hematoloji

Ankaferd® Kanama Durdurucunun HUVEC’lerde transkripsiyon faktörleri ve eritrosit protein profili üzerine etkisi

Öz:
Objective: Ankaferd® Blood Stopper (ABS) is an herbal extract that has historically been used as a hemostatic agent in traditional Turkish medicine. ABS is comprised of a standardized herbal mixture of T. vulgaris, G. glabra, V. vinifera, A. officinarum, and U. dioica. ABS’s basic mechanism of action is the formation of an encapsulated protein web, which represents the focal point for vital erythrocyte masses. The hemostatic effects of ABS have been observed in vitro and in vivo. ABS was registered as a hemostatic agent for external hemorrhages and dental bleeding following phase I randomized, double-blind crossover placebo-controlled clinical research, and safety and efficacy reports. In terms of the potential use of ABS, transcription factors may be novel factors that play a role in the hemo- static and other pleiotropic effects of ABS. Materials and Methods: Hence, the present study aimed to investigate the effects of ABS on endothe- lium, and possible transcription factor changes in HUVEC (human umbilical vein endothelial cells) and the erythrocyte membrane profile. ABS (5 μL and 50 μL) was administered to HUVEC (in 75 cm2; ~75% fullness) for 5 min and 15 min. Results: ABS caused significant increases in the level of activation of the following transcription fac- tors; AP2, AR, CRE/ATF1, CREB, E2F1-5, E2F6, EGR, GATA, HNF-1, ISRE, Myc-Max, NF-1, NFkB, p53, PPAR, SMAD 2/3, SP1, TRE/AP1, and YY1. Following erythrocyte membrane isolation, protein complexes were undissolved, but denatured. The protein complex formed was resistant to heat and detergent. Trypsin and sonication were used in order to break this complex; the complex dissolved and erythrocyte membrane proteins were released in SDS-PAGE. Conclusion: ABS established a very fast and solid protein web, and increased the level of transcription factor activation. Therefore the cellular effects of ABS could be related to different intracellular biological pathways.
Anahtar Kelime:

Konular: Hematoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat CH. Haemostatic actions of the folk- loric medicinal plant extract, Ankaferd Blood Stopper. Blood 2007;110:53be.
  • 2. Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat HC. Haemostatic actions of the folk- loric medicinal plant extract ankaferd blood Stoper. J Int Med Res 2008;36:163-70.
  • 3. Haznedaroglu IC. Time to take a healthier view of his- tory. Nature 1998;396:108. [CrossRef]
  • 4. Uçar Albayrak C, Calişkan U, Haznedaroglu IC, Goker H. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper Response. J Int Med Res 2008;36:1448-9.
  • 5. Akar N, Demiralp DO, Haznedaroglu IC, Goker H. Functional Proteomics of Ankaferd Blood Stopper. ASH Annual Meeting Abstracts 2008;112:4103.
  • 6. Aydin S. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2009;37:279.
  • 7. Demiralp DO, Haznedaroglu IC, Akar N. Functional Proteomics of Ankaferd Blood Stopper. Turkish Journal of Hematology 2010;27:70-7. [CrossRef]
  • 8. Arslan S, Haznedaroglu IC, Oz B, Goker H. Endobronchial application of Ankaferd blood stopper to control pro- fuse lung bleeding leading to hypoxemia and hemody- namic instability. Respiratory Medicine 2009;2:144-6.
  • 9. Erçetin S, Haznedaroğlu IC, Kurt M, Onal IK, Aktaş A, Kekilli M, Göker H, Özdemir O, Kirazlı S, Fırat HC. Safety and efficacy of Ankaferd BloodStopper® in den- tal surgery and bleeding. UHOD Int J Hematol Oncol 2010;20:1-5.
  • 10. Koray M, Ergun S, Saruhanoglu A, Tanyeri H. Use of a new local haemostatic agent Ankaferd blood stoper after surgical excision of eruption cyst: a case report. Int J Oral Maxillofac Surg 2009;38:558. [CrossRef]
  • Kurt M, Kacar S, Onal IK, Akdogan M, Haznedaroglu IC. Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threaten- ing arterial bleeding of the digestive tract. Endoscopy 2008;40:262. [CrossRef]
  • Akgül T, Huri E, Ayyıldız A, Üstün H, Germiyanoğlu C. The histopathological effects of Ankaferd BloodStopper®, a local medical plant extract, in mice penile fracture model: An experimental study. UHOD Int J Hematol Oncol 2009;19:159-65.
  • Bilgili H, Captug O, Kosar A, Kurt M, Kekilli M, Shorbagi A, Kurt OK, Ozdemir O, Goker H, Haznedaroglu IC. Oral systemic administration of Ankaferd blood stop- per has no short-term toxicity in an in vivo rabbit experimental model. Clin Appl Thromb Hemost 2010;16:533-6. [CrossRef]
  • Bilgili H, Kosar A, Kurt M, Onal IK, Goker H, Captug O, Shorbagi A, Turgut M, Kekilli M, Kurt OK, Kirazli S, Aksu S, Haznedaroglu IC. Hemostatic Efficacy of Ankaferd Blood Stopper (R) in a Swine Bleeding Model. Med Princ Pract 2009;18:165-9. [CrossRef]
  • Cipil HS, Kosar A, Kaya A, Uz B, Haznedaroglu IC, Goker H, Ozdemir O, Koroglu M, Kirazli S, Firat HC. In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfa- rin. Clin Appl Thromb Hemost 2009;15:270-6. [CrossRef]
  • Huri E, Akgul T, Ayyildiz A, Ustun H, Germiyanoglu C. Hemostatic role of a folkloric medicinal plant extract in a rat partial nephrectomy model: controlled experi- mental trial. J Urol 2009;181:2349-54. [CrossRef]
  • Huri E, Akgül T, Ayyıldız A, Üstün H, Germiyanoğlu C. The evaluation of the blood stopping effect of Ankaferd Bloodstopper® in major renal trauma: An animal experimentation. UHOD Int J Hematol Oncol 2010;20:206-11.
  • Karakaya K, Ucan HB, Tascilar O, Emre AU, Cakmak GK, Irkorucu O, Ankarali H, Comert M. Evaluation of a new hemostatic agent Ankaferd Blood Stopper in experimen- tal liver laceration. J Invest Surg 2009;22:201-6. [CrossRef] Epstein RJ. Human Molecular Biology. Cambridge: Cambridge University Press 2003;85-95.
  • Firat HC, Ozdemir O, Kosar A, Goker H, Haznedaroglu IC. Annual Review of Ankaferd 08-09. 2009, İstanbul: Naviga Publications 13-9.
  • Kumar D, Weatherall D. Genomics and Clinical Medicine (Oxford Monographs on Medical Genetics). Oxford University Press. 2004 Oxford 31-44.
  • Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H. The Molecular Basis of Blood Disease (3rd Edition). 2001, Philadelphia: W.B. Saunders, 81-102.
  • Watson JD, Baker TA, Bell SP Gann A, Levine M, Losick R. Molecular Biology of the Gene (5th Edition). 2004, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press 2004;347-77.
  • Kosar A, Cipil HS, Kaya A, Uz B, Haznedaroglu IC, Goker H, Ozdemir O, Ercetin S, Kirazli S, Firat HC. The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model. Blood Coagul Fibrinolysis 2009;20:185-90. [CrossRef]
  • Ucar Albayrak C, Caliskan U, Haznedaroglu IC, Goker H. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2008;36:1447-8.
  • Kurt M, Akdogan M, Onal IK, Kekilli M, Arhan M, Aksu S, Kurt OK, Haznedaroglu IC. Endoscopic topical appli- cation of Ankaferd Blood Stopper for neoplastic gastro- intestinal bleeding: a retrospective analysis. Dig Liver Dis 2010;42:196-9. [CrossRef]
  • Kurt M, Disibeyaz S, Akdogan M, Sasmaz N, Aksu S, Haznedaroglu IC. Endoscopic application of Ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: A case report. Am J Gastroenterol 2008;103:2156-8. [CrossRef]
  • Kurt M, Oztas E, Kuran S, Onal IK, Kekilli M, Haznedaroglu IC. Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability. Am J Emerg Med 2009;27:631. [CrossRef]
  • Haznedaroglu BZ, Haznedaroglu IC, Walker SL, Bilgili H, Goker H, Kosar A, Aktas A, Captug O, Kurt M, Ozdemir O, Kirazli S, Firat HC. Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper. Clin Appl Thromb Hemost 2010;16:446-53. [CrossRef]
  • Akkoc N, Akceik M, Haznedaroglu I, Goker H, Aksu S, Kirazli S, Firat H. In vitro anti-bacterial activities of ankaferd blood stopper. Int J Lab Hematol 2008;30:95.
  • Akkoc N, Akcelik M, Haznedaroglu IC, Goker H, Turgut M, Aksu S, Kirazli S, Firat HC. In Vitro Anti-Bacterial Activities of Ankaferd Medicinal Plant Extract. Turkiye Klinikleri Tip Bilimleri Dergisi 2009;29:410-5.
  • Fisgin NT, Cayci YT, Coban AY, Ozatli D, Tanyel E, Durupinar B, Tulek N. Antimicrobial activity of plant extract Ankaferd Blood Stopper. Fitoterapia 2009;80:48-50. [CrossRef]
  • Goker H, Cetinkaya D, Kilic E, Haznedaroglu IC, Kirazli S, Firat H. Anti-cancer activity of ankaferd blood stoper on osteosarcom (SAOS-2) cell lines in vitro, in Ankaferd: Scientific perspectives and basic-clinical data., G.H. Haznedaroglu I.C., Ozdemir O, Kosar A, Firat H, Editor. 2008, Naviga Publications: İstanbul:109.
  • Goker H, Kilic E, Cetinkaya D, Buyukasik Y, Aksu S, Turgut M, Haznedaroglu I, Anti-cancer activity of Ankaferd on human colon cancer (CACO-2) in vitro, in Ankaferd: Scientific Perspectives and Basic-Clinical Data, I.C. Haznedaroglu, et al., Editors. 2008, Naviga Publications: Istanbul:108.
  • Turhan N, Kurt M, Shorbagi A, Akdogan M, Haznedaroglu IC. Topical Ankaferd Blood Stopper administration to bleeding gastrointestinal carcinomas decreases tumor vasculariza- tion. Am J Gastroenterol 2009;10:2874-7. [CrossRef]
  • Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev 1999;18:377-85. [CrossRef]
  • Winger Q, Huang J, Auman HJ, Lewandoski M, Williams T. Analysis of transcription factor AP-2 expres- sion and function during mouse preimplantation development. Biol Reprod 2006;75:324-33. [CrossRef]
  • 38. Gruber R, Czerwenka K, Wolf F, Ho GM, Willheim M, Peterlik M. Expression of the vitamin D receptor, of estrogen and thyroid hormone receptor alpha- and beta-isoforms, and of the androgen receptor in cul- tures of native mouse bone marrow and of stromal/ osteoblastic cells. Bone 1999;24:465-73. [CrossRef]
  • 39. Karpinski BA, Morle GD, Huggenvik J, Uhler MD, Leiden JM. Molecular cloning of human CREB-2: an ATF/CREB transcription factor that can negatively regu- late transcription from the cAMP response element. Proc Natl Acad Sci U S A 1992;89:4820-4. [CrossRef]
  • 40. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609. [CrossRef]
  • 41. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009;9:785-97. [CrossRef]
  • 42. McMahon SB, Monroe JG. The role of early growth response gene 1 (egr-1) in regulation of the immune response. J Leukoc Biol 1996;60:159-66.
  • 43. Scharnhorst V, Menke AL, Attema J, Haneveld JK, Riteco N, van Steenbrugge GJ, van der Eb AJ, Jochemsen AG. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorige- nicity. Oncogene 2000;19:791-800. [CrossRef]
  • 44. Boulanger L, Sabatino DE, Wong EY, Cline AP Garrett LJ, Garbarz M, Dhermy D, Bodine DM, Gallagher PG. Erythroid expression of the human alpha-spectrin gene promoter is mediated by GATA-1- and NF-E2- binding proteins. J Biol Chem 2002;277:41563-70. [CrossRef]
  • 45. Pontoglio M. Hepatocyte nuclear factor 1, a transcrip- tion factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 2000;11:140-3.
  • 46. Spek CA, Lannoy VJ, Lemaigre FP Rousseau GG, Bertina RM, Reitsma PH. Type I protein C deficiency caused by disruption of a hepatocyte nuclear factor (HNF)-6/HNF-1 binding site in the human protein C gene promoter. J Biol Chem 1998;273:10168-73. [CrossRef]
  • 47. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 2000;61:1102-7. [CrossRef]
  • 48. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003;100:8164-9. [CrossRef]
  • 49. Shapira S, Barkan B, Friedman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 2007;14:895-906.
  • 50. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009;9:778-88. [CrossRef]
  • 51. Strachan T, Read AP Human molecular genetics 2. 1999, New York: Wiley.
  • 52. Seda O, Sedova L. Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes. Pharmacogenomics 2007;8:587-96. [CrossRef]
  • 53. Hill CS. Nucleocytoplasmic shuttling of Smad proteins. Cell Res 2009;19:36-46. [CrossRef]
  • 54. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008;40:383-408. [CrossRef]
  • 55. Cook T, Gebelein B, Urrutia R. Sp1 and its likes: bio- chemical and functional predictions for a growing fam- ily of zinc finger transcription factors. Ann NY Acad Sci 1999;880:94-102. [CrossRef]
  • 56. Zhao C, Meng A. Sp1-like transcription factors are regu- lators of embryonic development in vertebrates. Dev Growth Differ 2005;47:201-11. [CrossRef]
  • 57. Bernstein LR, Ben-Ari ET, Simek SL, Colburn NH. Gene regulation and genetic susceptibility to neoplastic transformation: AP-1 and p80 expression in JB6 cells. Environ Health Perspect 1991;93:111-9. [CrossRef]
  • 58. Hess J, Angel P Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004;117:5965-73. [CrossRef]
  • 59. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and thera- peutic implications in cancer biology. Oncogene 2006;25:1125-42. [CrossRef]
APA Yilmaz S, GÜLEÇ Ş, TORUN D, HAZNEDAROĞLU İ, akar n (2011). The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. , 276 - 285.
Chicago Yilmaz Serkan,GÜLEÇ ŞÜKRÜ,TORUN DİDEM,HAZNEDAROĞLU İbrahim Celalettin,akar nejat The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. (2011): 276 - 285.
MLA Yilmaz Serkan,GÜLEÇ ŞÜKRÜ,TORUN DİDEM,HAZNEDAROĞLU İbrahim Celalettin,akar nejat The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. , 2011, ss.276 - 285.
AMA Yilmaz S,GÜLEÇ Ş,TORUN D,HAZNEDAROĞLU İ,akar n The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. . 2011; 276 - 285.
Vancouver Yilmaz S,GÜLEÇ Ş,TORUN D,HAZNEDAROĞLU İ,akar n The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. . 2011; 276 - 285.
IEEE Yilmaz S,GÜLEÇ Ş,TORUN D,HAZNEDAROĞLU İ,akar n "The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile." , ss.276 - 285, 2011.
ISNAD Yilmaz, Serkan vd. "The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile". (2011), 276-285.
APA Yilmaz S, GÜLEÇ Ş, TORUN D, HAZNEDAROĞLU İ, akar n (2011). The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turkish Journal of Hematology, 28(4), 276 - 285.
Chicago Yilmaz Serkan,GÜLEÇ ŞÜKRÜ,TORUN DİDEM,HAZNEDAROĞLU İbrahim Celalettin,akar nejat The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turkish Journal of Hematology 28, no.4 (2011): 276 - 285.
MLA Yilmaz Serkan,GÜLEÇ ŞÜKRÜ,TORUN DİDEM,HAZNEDAROĞLU İbrahim Celalettin,akar nejat The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turkish Journal of Hematology, vol.28, no.4, 2011, ss.276 - 285.
AMA Yilmaz S,GÜLEÇ Ş,TORUN D,HAZNEDAROĞLU İ,akar n The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turkish Journal of Hematology. 2011; 28(4): 276 - 285.
Vancouver Yilmaz S,GÜLEÇ Ş,TORUN D,HAZNEDAROĞLU İ,akar n The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turkish Journal of Hematology. 2011; 28(4): 276 - 285.
IEEE Yilmaz S,GÜLEÇ Ş,TORUN D,HAZNEDAROĞLU İ,akar n "The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile." Turkish Journal of Hematology, 28, ss.276 - 285, 2011.
ISNAD Yilmaz, Serkan vd. "The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile". Turkish Journal of Hematology 28/4 (2011), 276-285.